Latest news with #NASDQ
Business Wire
5 days ago
- Business
- Business Wire
CCC Appoints Tech Leader Barak Eilam to Board of Directors
CHICAGO--(BUSINESS WIRE)-- CCC Intelligent Solutions Holdings Inc. (CCC) (NASDQ: CCCS), a leading cloud platform provider for the insurance and automotive industries, is pleased to announce the appointment of Barak Eilam to its Board of Directors. A seasoned technology executive and former CEO of NICE Ltd., Eilam brings more than two decades of experience in enterprise software, artificial intelligence (AI) and customer-engagement technologies. Mr. Eilam adds proven capabilities as CCC continues to scale growth from its strategic investments in AI, the CCC IX Cloud™ and its connected ecosystem. 'We are excited to welcome Barak to our Board as an independent director,' said Githesh Ramamurthy, Chairman and CEO of CCC. 'His experience scaling and driving customer-centric innovation will be a terrific addition to our ability to serve clients and help fuel our next phase of growth.' During his decade-long tenure as CEO of NICE, the company became an undisputed leader in AI-powered customer experiences, serving more than 25,000 organizations in more than 150 countries. Mr. Eilam led NICE through a period of accelerated growth, achieving nearly a threefold increase in revenue and a sevenfold rise in market capitalization. 'It's an honor to join CCC's Board at such a dynamic time,' said Eilam. 'CCC's laser focus on delivering value to its customers—reflected in its high customer satisfaction and retention—is truly impressive. I'm excited to support the company's mission to drive meaningful impact across the broader insurance and automotive industries.' The addition of Mr. Eilam reflects CCC's commitment to maintaining a Board of Directors with experienced and forward-thinking leaders to support the company's vision for growth and market expansion. Added Ramamurthy, 'As we welcome Barak, we also extend our sincere thanks to Chris Egan, who stepped down from the Board in March. We are deeply grateful for Chris's steadfast guidance, leadership and support since joining the board in 2017 as part of Advent International, L.P.'s investment in CCC.' About CCC CCC Intelligent Solutions Inc. (CCC), a subsidiary of CCC Intelligent Solutions Holdings Inc. (NASDAQ: CCCS), is a leading cloud platform provider for the multi-trillion-dollar P&C insurance economy, creating intelligent experiences for insurers, repairers, automakers, part suppliers, and more. The CCC Intelligent Experience (IX) Cloud™ platform, powered by proven AI and an innovative event-based architecture, connects more than 35,000 businesses to power customized applications and platforms for optimal outcomes and personalized experiences that just work. Through purposeful innovation and the strength of its connections, CCC technologies empower the people and industry relied upon to keep lives moving forward when it matters most. Learn more about CCC at Special Note Regarding Forward-Looking Statements This press release contains forward-looking statements that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'intend,' 'plan,' 'anticipate,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'ongoing' or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements regarding future use and performance of CCC's digital solutions. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, competition, including technological advances and new products marketed by competitors; changes to applicable laws and regulations; and other risks and uncertainties, including those included under the header 'Risk Factors' in CCC's filings with the Securities and Exchange Commission ('SEC'), including the Form 10-K filed February 25, 2025, which can be obtained, without charge, at the SEC's website ( The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.
Cision Canada
08-07-2025
- Business
- Cision Canada
Amid NCI Budget Fears, Emerging Oncology Stocks Gain Attention
VANCOUVER, BC, July 8, 2025 /CNW/ -- Equity Insider News Commentary – As cancer rates climb and drug costs continue to soar, pressure is mounting on the private sector to drive innovation. Now, cancer experts are alarmed over a "gut wrenching" plan from the U.S. government to cut nearly 40% of National Cancer Institute funding, even as the price of oncology treatments pushes new limits—raising urgent concerns about access and affordability. In this shifting landscape, investors are turning their attention to a new wave of biotechs and specialty care providers developing breakthrough therapies and smarter care models, including Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Celcuity Inc. (NASDAQ: CELC), Citius Oncology, Inc. (NASDQ: CTOR), Exelixis, Inc. (NASAQ: EXEL), and The Oncology Institute, Inc. (NASDAQ: TOI). Market forecasts suggest oncology could be one of the decade's fastest-growing sectors. Nova One Advisor projects the global oncology drug market will reach US$366.24 billion by 2034, with a 7.4% CAGR. Other firms are even more bullish— ResearchAndMarkets sees the market hitting US$866.1 billion, while Vision Research Reports expects revenue in 2034 to surpass US$903.81 billion, fueled by rising demand for advanced diagnostics and targeted therapies. For emerging cancer stocks, the timing couldn't be better. Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) has highlighted survival data that may redefine expectations for immunotherapy in cold tumors, especially in metastatic pancreatic and breast cancers, where treatment options remain limited. In first-line metastatic pancreatic ductal adenocarcinoma (mPDAC), Oncolytics's flagship pelareorep, an intravenously delivered immunotherapeutic agent, has a two-year overall survival rate of 21.9% across pooled data from more than 100 patients—more than double the historical benchmark of 9.2%. "We are no longer in the business of funding proof-of-concept studies," said Jared Kelly, newly-appointed CEO of Oncolytics. "We have meaningful clinical data in hand—not just signals. The survival benefit across multiple tumor types demands a focused approach to take pelareorep directly into registration-enabling trials. We will use our fast-track status to find the most efficient regulatory path forward this summer to advance our platform in a product technology." In a single-arm study combining pelareorep with chemotherapy and a checkpoint inhibitor, the objective response rate reached 62% in evaluable patients. No immunotherapy is currently approved in first-line metastatic pancreatic ductal adenocarcinoma. Breast cancer results are also very impressive. In HR+/HER2- metastatic breast cancer (mBC), pelareorep extended median overall survival by more than 10 months across two randomized trials compared to standard chemotherapy. In the BRACELET-1 trial, pelareorep plus paclitaxel delivered median progression-free survival of 12.1 months—nearly doubling the 6.4 months observed in the control arm. "Pelareorep represents a tipping point for immunotherapy in cold tumors," said Dr. Thomas Heineman, Chief Medical Officer of Oncolytics. "It is delivering consistent immunologic and clinical responses in multiple tumor types. Most impressively, pelareorep activates the immune system to produce clinical benefits in cancers that are typically unresponsive to immunotherapies." With over 1,100 patients studied to date, pelareorep continues to demonstrate a favorable safety profile, with most side effects limited to transient, flu-like symptoms. The company says it is now preparing for registration-enabling trials, leveraging its existing Fast Track designations in both mPDAC and HR+/HER2- mBC, as well as Orphan Drug status for pancreatic cancer in both the U.S. and Europe. The company recently reinforced its leadership bench with two high-profile appointments—naming Jared Kelly as Chief Executive Officer and Andrew Aromando as Chief Business Officer —as the company sharpens its focus on late-stage development and strategic transactions. Both men previously played key roles in Ambrx Biopharma's $2 billion acquisition by Johnson & Johnson and bring a track record of value creation in oncology-focused biotechs. Their arrival signals a deliberate pivot toward unlocking the value of pelareorep, Oncolytics' virus-based immunotherapy currently in multiple mid-to-late-stage studies. "Pelareorep's clinical data across multiple tumors is striking and represents the potential for a true backbone immunotherapy to address many in-need indications," said CEO Jared Kelly. "With a renewed focus and sharpened clinical development plan, we believe we will move pelareorep forward effectively and efficiently to a place where potential partners will see the value of a de-risked immunotherapy." As CBO, Aromando is now leading global business development and helping shape the company's corporate, clinical, and regulatory strategies. The leadership tandem is expected to prioritize partnering and expansion opportunities while preserving capital efficiency—a strategy well-suited for pelareorep's growing clinical profile. "I'm thrilled to join Oncolytics at such a pivotal moment in its evolution," said Aromando. "With promising data in difficult-to-treat cancers and a compelling body of clinical evidence in over 1,100 patients, I believe the Company is uniquely positioned to deliver meaningful value to patients and other stakeholders in the near term." Pelareorep holds FDA Fast Track designation in both metastatic pancreatic ductal adenocarcinoma (mPDAC) and HR+/HER2- metastatic breast cancer (mBC), and has shown encouraging synergy with checkpoint inhibitors and chemotherapy. In mPDAC, Phase 2 data showed objective response rates above 60% in tumor-evaluable patients, exceeding historical benchmarks, with survival at two years also outperforming expectations. Meanwhile, in HR+/HER2- mBC, two randomized phase 2 trials (IND-213 and BRACELET-1) demonstrated overall survival trends that support continued development. The drug's potential may extend even further. A Phase 2 anal cancer cohort combining pelareorep with a checkpoint inhibitor produced responses that surpassed historical checkpoint monotherapy outcomes, suggesting broader utility. Most recently, new data from the GOBLET trial presented at ASCO 2025 highlighted pelareorep's ability to activate both innate and adaptive immune responses in metastatic pancreatic cancer—reinforcing its potential as a backbone immunotherapy. With experienced leadership now in place and a growing clinical footprint, Oncolytics is advancing toward potential partnership, planning registration-enabling trials, and commercialization readiness—all while maintaining a disciplined, investor-aligned approach to capital and growth. In other recent industry developments and happenings in the market include: Celcuity Inc. (NASDAQ: CELC) has reported encouraging early-phase data from two separate clinical trials evaluating gedatolisib in prostate and breast cancer. In metastatic castration-resistant prostate cancer, a Phase 1 trial combining gedatolisib with darolutamide showed a 66% six-month radiographic progression-free survival rate. "We are very encouraged by this preliminary efficacy and safety data," said Igor Gorbatchevsky, MD, Chief Medical Officer of Celcuity. "The 66% six-month rPFS rate for this novel combination therapy compares favorably to published data for androgen receptor inhibitors in this setting. With no treatment-related discontinuations and less than 3% of patients experiencing Grade 3 stomatitis, we believe it is important to explore additional dose options for gedatolisib." In HER2+ metastatic breast cancer, a Phase 2 trial of gedatolisib plus standard doses of trastuzumab-pkrb showed a 43% objective response rate in patients who had received at least three prior lines of therapy. Citius Oncology, Inc. (NASDQ: CTOR) is preparing to launch LYMPHIR, an FDA -approved immunotherapy for relapsed or refractory cutaneous T-cell lymphoma, in the second half of 2025. "We've made steady and meaningful progress toward commercialization over the past several months," said Leonard Mazur, Chairman and CEO of Citius Oncology and Citius Pharma. "With our supply chain secured, market access supported, and no anticipated impediments to reimbursement, we are encouraged by the momentum we've built. These efforts are pivotal as we transition into a commercial-stage company and believe the planned 2025 launch of LYMPHIR has the potential to be an important inflection point for both the company and the CTCL community." The company has completed commercial-scale manufacturing, secured distribution partnerships, and built a launch strategy with AI-enhanced targeting of key oncology centers. With regulatory infrastructure in place and early clinical interest, Citius is positioned to transition into full commercial operations this year. Exelixis, Inc. (NASAQ: EXEL) reported positive Phase 3 results from its STELLAR-303 trial, showing that zanzalintinib combined with atezolizumab significantly improved overall survival versus regorafenib in patients with metastatic colorectal cancer. "The STELLAR-303 results, which showed a survival benefit with the combination of zanzalintinib and atezolizumab versus regorafenib across all randomized patients with previously treated metastatic colorectal cancer, marks an important first milestone for our zanzalintinib pivotal development program," said Amy Peterson, M.D., Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer, Exelixis. "We look forward to discussing the findings with regulatory authorities and presenting the detailed results at an upcoming medical conference." The combination met one of the trial's dual primary endpoints, and a final analysis for the second—overall survival in patients without liver metastases—is still pending. No new safety signals were observed, and full results are expected at an upcoming medical conference. The Oncology Institute, Inc. (NASDAQ: TOI) has entered into a major partnership with SilverSummit Healthplan to provide oncology care to over 80,000 Medicaid members across Nevada. "We couldn't be more excited about the opportunity to expand our partnership with SilverSummit and help create improved access and quality of cancer care to their Medicaid patient population," said Daniel Virnich, MD, CEO of The Oncology Institute. "We have a longstanding track record of providing outstanding care to Medicaid patients in other markets, and we look forward to broadening these efforts within the Las Vegas community." Effective July 1, TOI is now the exclusive provider of cancer services for SilverSummit's patient base, with dedicated clinics already open in Las Vegas, Henderson, and Spring Valley. The expansion reflects TOI's ongoing growth in value-based oncology, particularly among underserved populations. Both organizations emphasized the importance of delivering high-quality, community-based cancer care tailored to the needs of Medicaid patients. DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
Yahoo
03-07-2025
- Business
- Yahoo
Don't Sleep on Alphabet Stock This July
Shares of Alphabet Inc (NASDQ:GOOGL) are 0.7% lower to trade at $178.44 today, seeing pressure at the $180 level. The equity hosts a 5.7% year-to-date deficit, with its most recent pullback captured by the 50-day moving average. The equity could soon move back toward its February highs, however, as historically, July tends to be a good month for . More specifically, GOOGL has appeared on Schaeffer's Senior Quantitative Analyst Rocky White's list of the best 25 S&P 500 Index (SPX) stocks to own in the month of July over the past 10 years. For the month, GOOGL tends to average an 8.42% gain, finishing higher 90% of the time. Another move of this magnitude would put the tech behemoth back above $193 for the first time since early February. Now looks like a good time to weigh in with options, too. GOOGL's Schaeffer's Volatility Index (SVI) of 26% ranks in the 13th percentile of its annual range, meaning options traders are pricing in low volatility expectations. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17-03-2025
- Business
- Yahoo
Microsoft, Berkshire, And Waste Management Dominate Bill Gates' $44 Billion Foundation Portfolio
The Bill & Melinda Gates Foundation takes a highly concentrated approach to managing its endowment, with just three stocks accounting for 65% of its $44 billion equity portfolio, according to a document filed with the U.S. Securities and Exchange Commission last month. Microsoft (NASDQ: MSFT) leads the foundation's holdings at 28.5% of the portfolio, followed by Berkshire Hathaway (NYSE:BRK) (NYSE:BRK) at 21.2% and Waste Management (NYSE:WM) at 15.4%, reflecting both Gates' tech background and Warren Buffett's influence on the foundation's investment strategy. Don't Miss: Here's what Americans think you need to be considered wealthy. These five entrepreneurs are worth $223 billion – Since its inception as a global health initiative in 1994, the foundation has distributed $47.7 billion over three decades, making Bill and Melinda Gates the second most generous philanthropists behind only Warren Buffett and his family, according to The Motley Fool. Microsoft remains the largest position, with just under 28.5 million shares worth about $11.8 billion, stemming primarily from Gates' 2022 donation of more than 38 million shares. The trust has benefited from the stock's 70% surge since late 2022 amid growing AI investments. According to The Motley Fool, Microsoft's performance has been driven by its Azure cloud computing platform, which benefits from the company's $13 billion investment in OpenAI, and the integration of AI features into enterprise software through various Copilot products. Trending: The secret weapon in billionaire investor portfolios that you almost certainly don't own yet. Berkshire Hathaway is the second-largest holding, with 19.7 million Class B shares valued at approximately $9.5 billion. The shares come through Buffett's annual donations, according to The Motley Fool, though the trust typically sells some positions yearly to comply with Buffett's requirement that the foundation distribute his entire donation plus an additional 5% of its net assets annually. Despite selling 11% of its Berkshire stake last quarter, the foundation has maintained a dominant position in the company, which recently surpassed a $1 trillion valuation. Waste Management completes the top three holdings as one of the foundation's longest-held investments. The company recently acquired Stericycle and forecasts 16% revenue growth for 2025. The concentrated approach across technology, diversified holdings, and essential services has helped the foundation maintain its substantial endowment while continuing its global philanthropic mission. Read Next: Have $200K saved? Dogecoin millionaires are increasing – Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? APPLE (AAPL): Free Stock Analysis Report TESLA (TSLA): Free Stock Analysis Report This article Microsoft, Berkshire, And Waste Management Dominate Bill Gates' $44 Billion Foundation Portfolio originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
